A041703- A Phase II Study Of Inotuzumab Ozogamicin Followed By Blinatumomab For Ph-Negative Cd22-Positive B-Lineage Acute Lymphoblastic Leukemia In Newly Diagnosed Older Adults Or Adults With Relapsed Or Refractory Diseas
Posted Date: Nov 28, 2020
- Investigator: Emily Curran
- Specialties: Cancer, Leukemia, Oncology
- Type of Study: Drug
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. The primary goal of this study is to determine Event Free survival.
Criteria:
To Be Eligible: Must Have Morphologic Diagnosis Of Cd22-Positive Precursor B-Cell Acute Lymphoblastic Leukemia (All), Adequate Organ Function, Ecog 0-2, No Unstable Cardiac Disease Or Impaired Cardiac Function, No Additional Malignancy Within 2 Years, No Prior Treatment With Inotuzumab Ozogamicin, Blinatumomab, Other Cd22-Directed Therapy, Or Other Cd19-Directed Therapy
Keywords:
All, Leukemia
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com